AgomAb Therapeutics(AGMB.US)登陆美股市场 开盘跌超13%
Agomab Therapeutics NVAgomab Therapeutics NV(US:AGMB) Zhi Tong Cai Jing·2026-02-06 17:53

Group 1 - AgomAb Therapeutics (AGMB.US) debuted on the US stock market with an opening drop of over 13%, pricing its IPO at $16 [1] - The company is a clinical-stage biopharmaceutical firm focused on developing innovative disease-modifying therapies for immune and inflammatory diseases [1] - AgomAb's initial strategy targets chronic fibrotic indications with high unmet medical needs by inhibiting key signaling pathways involved in fibrosis, specifically the Transforming Growth Factor-beta (TGFβ) pathway [1] Group 2 - The core candidate drug, ontunisertib (AGMB-129), is a selective and potent oral small molecule inhibitor of ALK5 (TGFβR1), primarily aimed at treating fibrosing strictures in Crohn's disease (FSCD) [1]